Antinociceptive Profile of ARN19702, (2-Ethylsulfonylphenyl)-[(2S)-4-(6-fluoro-1,3-benzothiazol-2-yl)-2-methylpiperazin-1-yl]methanone, a Novel Orally Active N-Acylethanolamine Acid Amidase Inhibitor, in Animal Models
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Male mice and male rats in models of acute, inflammatory and neuropathic pain
- Dose used in the study
- ARN19702, an oral NAAA inhibitor, in a dose range; 30 mg/kg oral for the reward and motor tests. Palmitoylethanolamide itself was not given
- Duration
- Not stated in the abstract
- What was measured
- Formalin nocifensive response; hypersensitivity after carrageenan, paw incision, sciatic nerve ligation and paclitaxel; conditioned place preference; exploratory motor behaviour.
What the authors reported
This laboratory study found:
- Oral ARN19702 reduced formalin responses and hypersensitivity in the inflammatory, incision and nerve-ligation models in mice in a dose-dependent way, and reduced paclitaxel neuropathy pain in rats without subacute tolerance.
- At 30 mg/kg it did not produce place preference or change motor behaviour.
- NAAA breaks down palmitoylethanolamide, so the drug acts by preserving the body's own PEA.
Limits of this study
Rodent models; they cannot show effect in people. PEA was not given directly. One author is an inventor on patent applications for NAAA inhibitors owned by the University of California, Irvine.
Source
PubMed 33986036 · doi:10.1124/jpet.121.000674
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.